Abstract
Bruton's tyrosine kinase (Btk) is required for human and mouse B cell development. Btk deficiency causes X-linked agammaglobulinemia (XLA) in humans and X-linked immunodeficiency in mice. Unlike Src proteins, Btk lacks a negative regulatory domain at the COOH terminus and may rely on cytoplasmic Btk-binding proteins to regulates its kinase activity by trans-inhibitor mechanisms. Consistent with this possibility, IBtk, which we identified as an inhibitor of Btk, bound to the PH domain of Btk. IBtk downregulated Btk kinase activity, Btk-mediated calcium mobilization and nuclear factor-κB–driven transcription. These results define a potential mechanism for the regulation of Btk function in B cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
References
Tsukada, S., Rawlings, D. J. & Witte, O. N. Role of Bruton's tyrosine kinase in immunodeficiency. Curr. Opin. Immunol. 6, 623–630 (1994).
Yamada, N. et al. Structure and expression of novel protein-tyrosine kinases, Emb and Emt, in hematopoietic cells. Biochem. Biophys. Res. Commun. 192, 231–240 (1993).
Tsukada, S. et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 72, 279–290 (1993).
de Weers, M., Mensink, R. G., Kraakman, M. E., Schuurman, R. K. & Hendriks, R. W. Mutation analysis of the Bruton's tyrosine kinase gene in X-linked agammaglobulinemia: identification of a mutation which affects the same codon as is altered in immunodeficient xid mice. Hum. Mol. Genet. 3, 161–166 (1994).
Bruton, C. Agammaglogulinemia. Pediatrics 9, 722–731 (1952).
Vetrie, D. et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 361, 226–233 (1993).
Rawlings, D. J. et al. Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice. Science 261, 358–361 (1993).
Thomas, J. D. et al. Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes. Science 261, 355–358 (1993).
Uckun, F. M. et al. BTK as a mediator of radiation-induced apoptosis in DT-40 lymphoma B cells. Science 273, 1096–1100 (1996).
Scharenberg, A. M. & Kinet, J. P. PtdIns-3,4,5-P3: a regulatory nexus between tyrosine kinases and sustained calcium signals. Cell 94, 5–8 (1998).
Bajpai, U. D., Zhang, K., Teutsch, M., Sen, R. & Wortis, H. H. Bruton's tyrosine kinase links the B cell receptor to nuclear factor κB activation. J. Exp. Med. 191, 1735–1744 (2000).
Petro, J. B., Rahman, S. M., Ballard, D. W. & Khan, W. N. Bruton's tyrosine kinase is required for activation of IκB kinase and nuclear factor κB in response to B cell receptor engagement. J. Exp. Med. 191, 1745–1754 (2000).
Yang, W. & Desiderio, S. BAP-135, a target for Bruton's tyrosine kinase in response to B cell receptor engagement. Proc. Natl. Acad. Sci. USA 94, 604–609 (1997).
Novina, C. D. et al. Regulation of nuclear localization and transcriptional activity of TFII-I by Bruton's tyrosine kinase. Mol. Cell. Biol. 19, 5014–5024 (1999).
Fruman, D. A., Satterthwaite, A. B. & Witte, O. N. Xid-like phenotypes: a B cell signalosome takes shape. Immunity 13, 1–3 (2000).
Hendriks, R. W. et al. Inactivation of Btk by insertion of lacZ reveals defects in B cell development only past the pre-B cell stage. EMBO J. 15, 4862–4872 (1996).
Kerner, J. D. et al. Impaired expansion of mouse B cell progenitors lacking Btk. Immunity 3, 301–312 (1995).
Langhans-Rajasekaran, S. A., Wan, Y. & Huang, X. Y. Activation of Tsk and Btk tyrosine kinases by G protein βγ subunits. Proc. Natl. Acad. Sci. USA 92, 8601–8605 (1995).
Jiang, Y. et al. The G protein G α12 stimulates Bruton's tyrosine kinase and a rasGAP through a conserved PH/BM domain. Nature 395, 808–813 (1998).
Mao, J. et al. Tec/Bmx non-receptor tyrosine kinases are involved in regulation of Rho and serum response factor by Gα12/13. EMBO J 17, 5638–5646 (1998).
Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K. & Elledge, S. J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75, 805–816 (1993).
Vihinen, M., Nilsson, L. & Smith, C. I. Tec homology (TH) adjacent to the PH domain. FEBS Lett. 350, 263–265 (1994).
Schaeffer, E. M. et al. Requirement for Tec kinases Rlk and Itk in T cell receptor signaling and immunity. Science 284, 638–641. (1999).
Bolland, S., Pearse, R. N., Kurosaki, T. & Ravetch, J. V. SHIP modulates immune receptor responses by regulating membrane association of Btk. Immunity 8, 509–516 (1998).
Satterthwaite, A. B., Li, Z. & Witte, O. N. Btk function in B cell development and response. Semin. Immunol. 10, 309–316 (1998).
Andreotti, A. H., Bunnell, S. C., Feng, S., Berg, L. J. & Schreiber, S. L. Regulatory intramolecular association in a tyrosine kinase of the Tec family. Nature 385, 93–97 (1997).
Morrogh, L. M., Hinshelwood, S., Costello, P., Cory, G. O. & Kinnon, C. The SH3 domain of Bruton's tyrosine kinase displays altered ligand binding properties when auto-phosphorylated in vitro. Eur. J. Immunol. 29, 2269–2279 (1999).
Park, H. et al. Regulation of Btk function by a major autophosphorylation site within the SH3 domain. Immunity 4, 515–525 (1996).
Bence, K., Ma, W., Kozasa, T. & Huang, X. Y. Direct stimulation of Bruton's tyrosine kinase by G(q)-protein α-subunit. Nature 389, 296–299 (1997).
Fluckiger, A. C. et al. Btk/Tec kinases regulate sustained increases in intracellular Ca2+ following B-cell receptor activation. EMBO J. 17, 1973–1985 (1998).
Wahl, M. I. et al. Phosphorylation of two regulatory tyrosine residues in the activation of Bruton's tyrosine kinase via alternative receptors. Proc. Natl. Acad. Sci. USA 94, 11526–11533 (1997).
Rigley, K. P., Harnett, M. M., Phillips, R. J. & Klaus, G. G. Analysis of signaling via surface immunoglobulin receptors on B cells from CBA/N mice. Eur. J. Immunol. 19, 2081–2086 (1989).
Schaeffer, E. M. et al. Requirement for Tec kinases Rlk and Itk in T cell receptor signaling and immunity. Science 284, 638–641 (1999).
Rosen, F. S., Cooper, M. D. & Wedgwood, R. J. The primary immunodeficiencies. N. Engl. J. Med. 333, 431–440 (1995).
Vihinen, M. et al. BTKbase, mutation database for X-linked agammaglobulinemia (XLA). Nucleic Acids Res. 26, 242–247 (1998).
Bykowsky, M. J. et al. Discordant phenotype in siblings with X-linked agammaglobulinemia. Am. J. Hum. Genet. 58, 477–483 (1996).
Kornfeld, S. J. et al. A novel mutation (Cys145→Stop) in Bruton's tyrosine kinase is associated with newly diagnosed X-linked agammaglobulinemia in a 51-year-old male. Mol. Med. 2, 619–623 (1996).
Yao, L., Kawakami, Y. & Kawakami, T. The pleckstrin homology domain of Bruton tyrosine kinase interacts with protein kinase C. Proc. Natl. Acad. Sci. USA 91, 9175–9179 (1994).
Salim, K. et al. Distinct specificity in the recognition of phosphoinositides by the pleckstrin homology domains of dynamin and Bruton's tyrosine kinase. EMBO J. 15, 6241–6250 (1996).
Endo, T. A. et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387, 921–924 (1997).
Starr, R. et al. A family of cytokine-inducible inhibitors of signalling. Nature 387, 917–921 (1997).
Vassilev, A., Ozer, Z., Navara, C., Mahajan, S. & Uckun, F. M. Bruton's tyrosine kinase as an inhibitor of the Fas/CD95 death-inducing signaling complex. J. Biol. Chem. 274, 1646–1656 (1999).
Futatani, T. et al. Deficient expression of Bruton's tyrosine kinase in monocytes from X-linked agammaglobulinemia as evaluated by a flow cytometric analysis and its clinical application to carrier detection. Blood 91, 595–602 (1998).
Hata, D. et al. Involvement of Bruton's tyrosine kinase in FcɛRI-dependent mast cell degranulation and cytokine production. J. Exp. Med. 187, 1235–1247 (1998).
Oda, A. et al. Rapid tyrosine phosphorylation and activation of Bruton's tyrosine/Tec kinases in platelets induced by collagen binding or CD32 cross-linking. Blood 95, 1663–1670 (2000).
Guinamard, R., Aspenstrom, P., Fougereau, M., Chavrier, P. & Guillemot, J. C. Tyrosine phosphorylation of the Wiskott-Aldrich syndrome protein by Lyn and Btk is regulated by CDC42. FEBS Lett. 434, 431–436. (1998).
Ambrosino, C. et al. HIV-1 Tat induces the expression of the interleukin-6 (IL6) gene by binding to the IL6 leader RNA and by interacting with CAAT enhancer–binding protein β (NF-IL6) transcription factors. J. Biol. Chem. 272, 14883–14892 (1997).
Stewart, D. M., Notarangelo, L. D., Kurman, C. C., Staudt, L. M. & Nelson, D. L. Molecular genetic analysis of X-linked hypogammaglobulinemia and isolated growth hormone deficiency. J. Immunol. 155, 2770–2774 (1995).
Giordano, V. et al. Shc mediates IL-6 signaling by interacting with gp130 and Jak2 kinase. J. Immunol. 158, 4097–4103 (1997).
Rabin, R. L. et al. Chemokine receptor responses on T cells are achieved through regulation of both receptor expression and signaling. J. Immunol. 162, 3840–3850 (1999).
Pine, R., Canova, A. & Schindler, C. Tyrosine phosphorylated p91 binds to a single element in the ISGF2/IRF-1 promoter to mediate induction by IFN α and IFN γ, and is likely to autoregulate the p91 gene. EMBO J. 13, 158–167. (1994).
Chen, X. et al. Impaired generation of bone marrow B lymphocytes in mice deficient in C/EBPβ. Blood 90, 156–164. (1997).
Dyson, N. The regulation of E2F by pRB-family proteins. Genes Dev. 12, 2245–2262. (1998).
Acknowledgements
We thank S. J. Elledge for the B cell cDNA library in pACT; F. A. Uckun for the DT40 cells; P. M. Schwartzberg for pBS-ItkF P; M. Ghedina for pZ-STAT; and J. J. O'Shea, M. J. Lenardo and P. L. Schwartzberg for careful reading of the manuscript. Supported by grants from AIRC, ISS, Telethon and MURST.
Author information
Authors and Affiliations
Corresponding author
Supplementary information
Web Figure 1.
IBtk does not associate with Itk Tec kinase. 293T cells were transfected with pCDNA-IBtk together with pBS-ItkF, a plasmid expressing a Itk-FLAG fusion protein. Cell lysates from transfected cells were subjected to immunoprecipitation with anti-IBtk antibody to peptide 1 followed by immunoblotting with anti-Itk mAb (Upstate). No detectable Itk was recovered from immunoprecipitated proteins (lane 1). Itk was detected by immunoblotting in the cell lysate (20 µg) (lane 2). Expression of IBtk in lysates (20 µg) from transfected cells was detected by immunoblotting (lower panel). (GIF 10 kb)
41590_2001_BFni1001939_MOESM2_ESM.gif
Web Figure 2. IBtk does not interfere with the NF-κB activation induced by PMA in DT40 B cells. DT40 WT cells were transfected with pNF-κB-Luc (5 µg) and pCDNA-IBtk together with pRLTK plasmid. 16 h after transfection, cell aliquots were treated either with M4 anti-IgM or with phorbol 12-myristate 13-acetate (PMA) (10 ng/ml). Cell extracts were assayed for luciferase activity as detailed in Methods. (GIF 20 kb)
41590_2001_BFni1001939_MOESM3_ESM.gif
Web Figure 3. IBtk interference with the induction of transcription factors. MC3 cells (a, b, c) and Jurkat cells (d) were transfected with a mixture of 10 µg of pCDNA-IBtk, 5 ˙g of luciferase reporter plasmids and 2 µg of pRLTK plasmid expressing Renilla luciferase gene. (a) pZSTAT-Luc carries the STAT binding site of the IGF2/IRF promoter that is responsive to IFN-γ51; (b) pC/EBP-Luc carries the interleukin-6 (IL-6)-responsive cis-binding site of IL-6 promoter52; (c) pE2F-Luc harbors the E2F responsive sequence of E2F gene, which is activated during cell cycle progression53. After 16 h, cells were (a) stimulated for 12 h with interferon-γ (10 ng/ml, Genzyme [AUTHOR: location?]), (b) stimulated for 12 h with IL-6 (50 ng/ml, Genzyme), or (c) left untreated. (d) Jurkat cells were transfected with pNFAT-Luc (5 µg, Clontech) and stimulated with anti-CD3 (5 µg, Pharmingen) followed by goat anti-mouse antibody (5 µg, Caltag) to cross-link the TCR. Transcriptional levels were not affected by the expression of IBtk. (GIF 24 kb)
Rights and permissions
About this article
Cite this article
Liu, W., Quinto, I., Chen, X. et al. Direct inhibition of Bruton's tyrosine kinase by IBtk, a Btk-binding protein. Nat Immunol 2, 939–946 (2001). https://doi.org/10.1038/ni1001-939
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ni1001-939
This article is cited by
-
Activation of NF-κB in B cell receptor signaling through Bruton’s tyrosine kinase-dependent phosphorylation of IκB-α
Journal of Molecular Medicine (2019)
-
CircIBTK inhibits DNA demethylation and activation of AKT signaling pathway via miR-29b in peripheral blood mononuclear cells in systemic lupus erythematosus
Arthritis Research & Therapy (2018)
-
Role of Bruton’s tyrosine kinase in B cells and malignancies
Molecular Cancer (2018)
-
The expression of inhibitor of bruton’s tyrosine kinase gene is progressively up regulated in the clinical course of chronic lymphocytic leukaemia conferring resistance to apoptosis
Cell Death & Disease (2018)
-
A novel oncogenic BTK isoform is overexpressed in colon cancers and required for RAS-mediated transformation
Oncogene (2016)